AUTHORS
Sandhya Panch, MD, Bruno Fattizzo, MD2, Irina Murakhovskaya, MD3, Yasutaka Ueda, MD, PhD4, Sue Pavord, MBBS5, David Simcox6, Wayne Thomas7, Doug Schlichting, PhD8, Kristen Sweet, PhD9, Michael Zelasky10, Jagriti Craig11, Leona E. Ling12, Amuche Anakor13, Cathye Shu14
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington School of Medicine, Seattle, Washington, United States
2 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, Hematology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
3 Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, United States
4 The University of Osaka, Suita, Osaka, Japan
5 Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
6 Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
7 University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
8 Johnson & Johnson, Spring House, Pennsylvania, United States
9 Johnson & Johnson, Spring House, Pennsylvania, United States
10 Johnson & Johnson, Spring House, Pennsylvania, United States
11 Johnson & Johnson, Raritan, New Jersey, United States
12 Johnson & Johnson, Cambridge, Massachusetts, United States
13 Johnson & Johnson, Spring House, Pennsylvania, United States
14 Johnson & Johnson, Spring House, Pennsylvania, United States
ABSTRACT
Background: Nipocalimab is a fully human IgG1 monoclonal antibody that selectively blocks the neonatal Fc receptor, thereby preventing endogenous IgG recycling and leading to a rapid and substantial reduction in immunoglobulin G (IgG). Nipocalimab is approved in generalized myasthenia gravis and is in clinical development in multiple therapeutic areas. Data evaluating IgG responses to routine vaccinations or infection in nipocalimab-treated clinical trial participants with different IgG autoantibody-mediated diseases (eg, generalized myasthenia gravis, Sjögren’s disease, and rheumatoid arthritis) suggested that nipocalimab did not interfere with the development of effective immunity following vaccination and/or infection. In the phase 2/3, randomized, double-blind, placebo-controlled ENERGY study (NCT04119050) of participants with warm autoimmune hemolytic anemia (wAIHA) who have previously received or are currently receiving treatment for wAIHA, treatment with nipocalimab 30 mg/kg intravenous (IV) every 4 weeks (q4w) or 15 mg/kg IV every 2 weeks (q2w) resulted in rapid IgG reductions. Nipocalimab 30 mg/kg IV q4w demonstrated significant benefit in durable hemoglobin response. Safety findings were consistent with nipocalimab’s known safety profile and wAIHA-associated risks. Overall rates of infections were comparable between the combined nipocalimab and placebo groups (45.3% and 41.0%, respectively), including serious infections, which were no higher than placebo (5.3% vs 10.3%, respectively). No hypogammaglobulinemia (<1 g/L) was observed.
Aim: The objective of this analysis was to explore whether there is an association between IgG reduction and infection rates in participants with wAIHA treated with nipocalimab from the double-blind period of ENERGY.
Methods: A Receiver Operating Characteristic (ROC) analysis was conducted to assess whether IgG levels (at baseline and maximum change from baseline) were associated with infection rates in participants from the ENERGY study. Both analyses included occurring after the maximum change from baseline IgG was achieved. Area-Under-the-Curve (AUC) values were calculated using logistic regression ROC analysis with baseline IgG, maximum change from baseline in IgG, and treatment group as covariates. AUC values range from 0 to 1, with 0.5 to 0.7 indicating no/poor discrimination (equivalent to chance/poor discrimination), 0.7 to 0.8 indicating fair discrimination, and higher values reflecting predictive association (0.8 to ≤0.9, excellent discrimination).
Results: A total of 115 participants were randomized in ENERGY; 55% of participants were female, 46% were White, and 87% had primary wAIHA. A total of 78 nipocalimab-treated participants were included in safety analyses; 79% (n=62), 65% (n=51), 55% (n=43), and 29% (n=23) had a post-baseline nadir IgG level ≤5 g/L, ≤4 g/L, ≤3 g/L, and ≤2 g/L, respectively. No participants had a nadir IgG ≤1 g/L. ROC analysis for baseline IgG and infection showed AUC (standard error) of: 0.757 (0.064) for participants with nadir IgG ≤5 g/L (25.36 patient-years of exposure); 0.723 (0.074) for nadir IgG ≤4 g/L (20.61 patient-years of exposure); 0.715 (0.083) for nadir IgG ≤3 g/L (17.23 patient-years of exposure); and 0.706 (0.113) for nadir IgG ≤2 g/L (9.45 patient-years of exposure). ROC analysis for maximum change from baseline in IgG and infection showed AUC (standard error) of: 0.685 (0.069) for participants with nadir IgG ≤5 g/L; 0.678 (0.075) for nadir IgG ≤4 g/L; 0.692 (0.082) for nadir IgG ≤3 g/L; and 0.679 (0.116) for nadir IgG ≤2 g/L. These values indicate that the predictive value of baseline IgG levels on infection are considered fair and of limited clinical utility. The predictive power of reduced post-baseline IgG levels on infection occurrence was generally equivalent to chance, even at IgG levels ≤2 g/L.
Conclusion: These results do not show an association between reduction in IgG levels with nipocalimab and the incidence of infections in participants with wAIHA in the phase 2/3 ENERGY study. These findings are consistent with the immunoselective mechanism of nipocalimab, which blocks FcRn and selectively lowers IgG, while preserving key humoral and cellular immune functions and response to immunization or infectious agents.
DISCLOSURES
Sandhya Panch, MD: Novartis - Honoraria; Sobi - Honoraria; Sanofi - Honoraria; Amgen, Argenyx, J&J, Novartis, Sanofi, Sobi, and Recordati - Research Funding; Incyte, Novartis, Uoro Med., Sanofi, SOBI, and Takeda - Research Funding; Amgen, Argenyx, J&J, Novartis, Sanofi, Sobi, and Recordati - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)